Antiallergic drugs and quality of life

References

• Isolauri E, Huurre A, Salminem S, Impivaara O. The allergy epidemic extends beyond the past two decades. Clin. Exp. Allergy 34(7), 1007–1010 (2004).
   PubMed Web of Science ®Google Scholar
• Gerth van Wijk R. Allergy: a global problem. Quality of life. Allergy 57(12), 1097–1110 (2002).
   PubMedGoogle Scholar
• Bousquet J, Van Cauwenberge P, Khaltaev N et al. Rhinitis and its impact on asthma (ARIA) in collaboration with the World Health Organization (WHO). J. Allergy Clin. Immunol. 108, S147–S336 (2001).
   PubMed Web of Science ®Google Scholar
• Fumagalli F, Baiardini I, Pasquali M et al. Antihistamines: do they work? Further well-controlled trials involving larger samples are needed. Allergy 59, 74–77 (2004).
   PubMedGoogle Scholar
• Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 23(6), 391–398 (2002).
   PubMed Web of Science ®Google Scholar
• Noonan MJ, Raphael GD, Nayak A et al. The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin. Exp. Allergy 33(3), 351–358 (2003).
   PubMedGoogle Scholar
• Bachert C, Bousquet J, Canonica GW et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J. Allergy Clin. lmmunol. 114(4), 838–834 (2004).
   Google Scholar
• Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M, Crawford B. Fexofenadine improves quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int. Arch. Allergy Immunol. 136(2), 148–154 (2005).
   PubMed Web of Science ®Google Scholar
• Satish U, Streufert S, Dewan M, Vande Voort S. Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. Allergy 59(4), 415–420 (2004).
   PubMed Web of Science ®Google Scholar
• Juniper EF, Price DB, Stampone PA, Creemers JP, Mol SJM, Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest121(6), 1824–1832 (2002).
   PubMed Web of Science ®Google Scholar
• Fish JE, Karpel JP, Craig TJ et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J. Allergy Clin. Immunol. 106(6), 852–860 (2000).
   PubMed Web of Science ®Google Scholar
• Everden P, Campbell M, Harnden C et al. Eformeterol turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids. Pediatr. Allergy Immunol. 15, 40–47 (2004).
   PubMedGoogle Scholar
• Price D, Dutchman D, Mawson A, Bodalia B, Duggan S, Todd P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax 57, 791–798 (2002).
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Canonica GW. Long-lasting clinical efficacy of allergen specific immunotherapy. Allergy 57(4), 275–276 (2002).
   PubMedGoogle Scholar
• Walker SM, Pajno GB, Torres Lima M, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J. Allergy Clin. Immunol. 107, 87–93 (2001).
   PubMed Web of Science ®Google Scholar
• Arikan C, Bahceciler NN, Deniz G et al. Bacillus Calmette-Guerin-induced interleukin-12 did not additionally improve clinical and immunologic parameteres in asthmatic children treated with sublingual immunotherapy. Clin. Exp. Allergy 34, 398–404 (2004).
   PubMed Web of Science ®Google Scholar
• Radcliffe MJ, Lewith GT, Turner RG, Prescott P, Church MK, Holgate ST. Enzyme potentiated desensitisazion in treatment of seasonal allergic rhinitis: double-blind randomized controlled study. Br. Med. J. 327(2), 251–258 (2003).
   PubMedGoogle Scholar
• Oude Elberink JNG, de Monchy JGR, van der Heide S, Guyatt GH, Dubois AEJ. Venom immunotherapy improves health-related quality of life in patients allergic to yello jacjet venom. J. Allergy Clin. Immunol. 110(1), 174–182 (2002).
   PubMed Web of Science ®Google Scholar
• Davydov L. Omalizumab (Xolair) for treatment of asthma. Am. Fam. Physician 71(2), 341–342 (2005).
   PubMedGoogle Scholar
• Buhl R, Hanf G, Soler M et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur. Respir. J. 20, 1088–1094 (2002).
   PubMed Web of Science ®Google Scholar
• Oba Y, Salzman GA. Cost–effectiveness analysis of omalizumab in adults and adolescent with moderate-to-severe allergic asthma. J. Allergy Clin. Immunol.114, 265–269 (2004).
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment) INNOVATE. Allergy 60, 309–316 (2005).
   PubMed Web of Science ®Google Scholar
• Novak N, Kwiek B, Bieber T. The mode of topical immunomodulators in the immunological network of atopic dermatitis. Clin. Exp. Dermatol. 30(2), 160–164 (2005).
   PubMed Web of Science ®Google Scholar
• Whalley D, Huels J, McKenna S, Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents’ quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 110(6), 1133–1136 (2002).
   PubMed Web of Science ®Google Scholar
• Drake L, Prendegarst M, Maher R et al. The impact of tacrolimus on health-related quality of life of adult and pediatric patients with atopic dermatitis. J. Am. Acad. Dermatol. 44(19), S65–S72 (2001).
   PubMed Web of Science ®Google Scholar
• Milanese M, Passalacqua G, Pasquali M, Baiardini I, Canonica GW. Role of leukotriene receptor antagonists in the management of mild-to-moderate asthma. Monaldi Arch. Chest Dis. 56(6), 508–513 (2001).
   PubMedGoogle Scholar
• Philip G, Nayak AS, Berger WE et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr. Med. Res. Opin. 20(10), 1549–1558 (2004).
   PubMed Web of Science ®Google Scholar
• Nettis E, Colonardi MC, Paradiso MT, Ferranini A. Desloratadine in combination with montelukast in treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin. Exp. Allergy 34, 1401–1407 (2004).
   PubMed Web of Science ®Google Scholar
• Murphy KR, Fitzpatrick S, Cruz-Rivera M, Miller CJ, Parasuraman B. Effect of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma. Pediatrics 112(3), 212–219 (2003).
   Web of Science ®Google Scholar
• Rutherford C, Mills R, Gibson PG, Price MJ. Improvement in health-related quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma. Respirology 8, 371–375 (2003).
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Canonica GW, Grosclaude M, Ostinelli J, Brazzola GG, Bousquet J. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 57(7), 586–591 (2002).
   PubMed Web of Science ®Google Scholar
• Baiardini I, Pasquali M, Giardini A et al. Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy 58(4), 289–294 (2003).
   PubMed Web of Science ®Google Scholar
• Baiardini I, Braido F, Fassio O et al. A new tool to assess and monitor the burden of chronic cough on quality of life: chronic cough impact questionnaire. Allergy 60(4), 482–488 (2005).
   PubMed Web of Science ®Google Scholar
• Baiardini I, Pasquali M, Braido F et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy 60(8), 1073–1078 (2005).
   PubMedGoogle Scholar